Physician profile
Robert Galamaga
NPI 1891805446
$168,430.16
in general payments reported to CMS, 2019-2025
75 companies · $7,278 in 2025
The $7,278 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $4,602 · 2021: $18K · 2022: $31K · 2023: $54K · 2024: $40K · 2025: $7,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Consulting Fee: $35K · Food and Beverage: $7,287 · Travel and Lodging: $2,620 · Education: $612 · Honoraria: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,038.50 |
| Consulting Fee | $35,450.25 |
| Food and Beverage | $7,287.06 |
| Travel and Lodging | $2,619.92 |
| Education | $611.95 |
| Honoraria | $360.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $62,950.43 | 2022-2025 | |
| F. Hoffmann-La Roche Ag | $25,350.00 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $22,692.65 | 2019-2025 | Imfinzi, Lynparza, Enhertu |
| Celgene Corporation | $10,623.30 | 2019-2025 | Reblozyl, Pomalyst |
| Mirati Therapeutics, INC. | $4,507.88 | 2023-2024 | Krazati |
| Rigel Pharmaceuticals, INC. | $3,768.77 | 2019-2022 | |
| Dova Pharmaceuticals | $3,716.19 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $3,285.00 | 2023-2024 | Imbruvica |
| Servier Pharmaceuticals LLC | $3,211.34 | 2022-2025 | |
| Roche Diagnostics International LTD | $3,181.50 | 2025 | |
| Glaxosmithkline, LLC. | $2,861.06 | 2021-2024 | Ojjaara |
| Seagen INC. | $2,353.34 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Ipsen Biopharmaceuticals, INC | $2,307.13 | 2019-2025 | Tazverik, Onivyde |
| Incyte Corporation | $2,000.84 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Astellas Pharma Global Development | $1,750.00 | 2022 |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Galamaga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.